-MolecuLight featured in an unprecedented 24 presentations and posters at the European Wound Management Association (EWMA) Annual Conference 2023
Extensive clinical evidence from the MolecuLight imaging platform reveals its significant global adoption and proven utility in wound care
TORONTO and MILAN, May 3, 2023 /PRNewswire/ -- MolecuLight Inc., a leader in point-of-care fluorescence imaging that detects and localizes elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in 24 Unprecedented presentations and posters at the European Wound Management Association (EWMA) 2023 Annual Conference, taking place May 3-5, 2023 in Milan, Italy. Held annually, EWMA is Europe's largest wound care conference and one of the world's largest events for wound care professionals.
"We are humbled by the number of clinicians around the world who have made our MolecuLight point-of-care device an invaluable tool in their wound care practices," said Anil Amlani, CEO of MolecuLight. "The impressive collection of 24 talks and posters from so many centers around the world shows how the MolecuLight imaging device is becoming a new standard of care in wound care. This clinical evidence is reflected in the more than 75 peer-reviewed publications in pairs, showing the significant benefit of MolecuLight i:X® and DX™ for clinical wound assessment, practice and outcomes."
"The MolecuLight imaging platform is a 'must have' device for wound care clinics and is a standard of care in our clinics. The abundance of published clinical evidence showing improvements in bioburden detection, better clinical decisions and improved outcomes is clear validation of its medical necessity," said Thomas Serena, MD, Founder and Medical Director of The SerenaGroup® and Author and Presenter of 2 MolecuLight Talks and Posters at EWMA 2023. "There are tangible clinical benefits for the use of MolecuLight in conjunction with a wide range of wound care procedures, in all wound care settings Evidence now demonstrates that clinical signs and symptoms are insufficient and contribute to the random prescription of antimicrobials and antibiotics. Added to clinical assessment, MolecuLight imaging information pinpoints risk wounds earlier, leading to proactive management of bacterial infection, reduced overprescription of antibiotics, fewer complications of infection, and faster healing quick".
The collection of 9 presentations and 15 posters featuring MolecuLight imaging devices show how the devices inform clinical decision making through their digital wound measurement function, detection of high bacterial load in bedside wounds, and its ability to monitor and track wound size and bioburden over time. The studies presented cover the entire wound care process, including:
The results presented illustrate the significant clinical improvements in multiple aspects of wound care provided by the MolecuLight platform.
A selection of the posters and clinical presentations featuring MolecuLight i:X and DX from the European Wound Management Association (EWMA) 2023 Annual Conference are:
(a) Some ClinicalPosters citing the MolecuLight point-of-care device are:
(b) Selected clinical presentations citing the MolecuLight point-of-care device include:
The complete list of the 24 presentations and posters is available here.
MolecuLight i:X and DX are the only imaging devices for real-time detection of elevated bacterial load in wounds that are FDA cleared, CE marked and Health Canada approved. With clinical trials including more than 75 peer-reviewed publications, the devices are used by leading wound care centers around the world.
About MolecuLight Inc.
MolecuLight Inc. is a privately held medical imaging company that has developed and markets its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and accessories, are portable point-of-care imaging devices for real-time detection and localization of bacterial load. in wounds and digital measurement of wounds. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway that includes two CPT® codes for physician work to perform "fluorescence imaging for presence, location, and load of bacteria" and facility payment for the Hospital Outpatient Department (HOPD) and the Ambulatory Surgical Center (ASC) through an Outpatient Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology to other global markets with relevant unmet needs in food safety, consumer cosmetics, and other key industrial markets.
Rob Sandler, responsable de Marketing, MolecuLight Inc., T. 1.647.362.4684, email@example.com, www.moleculight.com
Photo - https://mma.prnewswire.com/media/2068521...
View original content: https://www.prnewswire.com/news-releases/moleculight-destaco-en-24-presentaciones-y-posteres-en-la-conferencia-anual-2023-de-la-ewma-301814644.html